Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL.
CAR-T therapy extended progression-free survival compared to bispecific antibodies in blood cancers, though it required more healthcare contact in the first year.
This multicenter retrospective comparative cohort examined comparative survival and health-care contact burden with CAR-T versus bispecific antibody therapy. CAR-T was associated with longer progression-free survival but greater first-year health-care contact burden than bispecific antibody therapy.
What the study was
- Study design
- Multicenter retrospective comparative cohort
- Population
- 228 patients with relapsed or refractory follicular lymphoma
- Sample size
- 228
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood advances
Why it surfaced
Retained as a high-priority multicenter retrospective comparative cohort after PubMed abstract review; the score reflects clinical relevance, design strength, novelty, and population need under the v1.3 conservative rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.